CLBT INVESTIGATION: Cellebrite Investigated by Block & Leviton; Investors Should Contact the Firm to Possibly Recover Losses

Boston, Massachusetts--(Newsfile Corp. - October 2, 2026) - Block & Leviton is investigating Cellebrite DI (NASDAQ: CLBT) for potential securities law violations. Investors who have lost money in their Cellebrite DI investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/clbt.

Block & Leviton is investigating whether Cellebrite and certain of its executives may have violated the federal securities laws. In May 2026, Cellebrite's then-CEO told investors that its U.S. federal business was "beginning to accelerate" and pointed to a meaningful pipeline of large government deals expected to close in the second quarter. On August 13, 2026, the company reported second-quarter results that missed revenue and earnings estimates and cut its full-year annual recurring revenue guidance by roughly $15 million at the midpoint, blaming a handful of large federal and European government deals that slipped out of the quarter due to newly encountered procurement and "foreign entity permit" requirements, as well as weaker-than-expected pricing on "Insights" conversions. The company simultaneously announced an abrupt CEO change, replacing Tom Hogan with Shiv Ramji effective the same day. Cellebrite shares fell approximately 32% on the news. The investigation concerns whether the company adequately disclosed the risks to its government pipeline when it was reassuring investors earlier in the year.